Transcranial magnetic stimulation pioneer Neuronetics has picked up a new FDA clearance that builds its position in obsessive-compulsive disorder (OCD), a major new application of the technology.
CARY, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Greenbrook TMS NeuroHealth Centers, one of the leading providers of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today ...
The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...
BURLINGTON, Mass. and JERUSALEM, June 21, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...
Transcranial magnetic stimulation sounds like — and looks like — something you'd find in a science fiction movie, but it's a real treatment option. This noninvasive therapy uses strong magnets to ...
With this expanded portfolio, our users can now choose the most appropriate coil for each specific patient, prioritizing comfort, treatment precision, and outcomes.” — Kerry Rome, SVP MagVenture, Inc.
Brainsway will prepare a submission to the FDA to market the device for OCD Deep TMS treatment led to statistically significant and meaningful improvements in patients suffering from OCD Patients who ...
Moment of Clarity has released a new resource, titled “Using TMS Therapy for BPD Recovery,” now available on their website.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback